Pancreatic cholera syndrome

Effect of a synthetic somatostatin analog on intestinal water and ion transport

W. C. Santangelo, T. M. O'Dorisio, J. G. Kim, G. Severino, G. J. Krejs

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The effect of a synthetic somatostatin analog was studied in a patient with severe secretory diarrhea due to pancreatic cholera syndrome. Basal intestinal perfusion studies indicated an absence of water and sodium absorption, and active chloride secretion in the small bowel. Intravenous administration of the somatostatin analog (1 μg/kg.hr) changed zero net water movement to absorption (122 mL/30 cm of the jejunum per hour). Chloride secretion changed to absorption (5.0 to 7.9 meq/30 cm.h), and plasma vasoactive intestinal polypeptide concentration was reduced from 330 to 45 pmol/L (normal, less than 51). When the analog was given subcutaneously, 100 μg twice daily, stool weight decreased, and plasma vasoactive intestinal polypeptide concentration fell toward the normal range (67 pmol/L). Plasma concentration of pancreatic polypeptide was initially elevated and dropped during intravenous infusion of somatostatin analog but returned to baseline on maintenance therapy with the analog delivered subcutaneously. The patient has not had further diarrhea during 9 months of therapy.

Original languageEnglish (US)
Pages (from-to)363-367
Number of pages5
JournalAnnals of Internal Medicine
Volume103
Issue number3
StatePublished - Dec 4 1985

Fingerprint

Vipoma
Ion Transport
Somatostatin
Vasoactive Intestinal Peptide
Water
Chlorides
Diarrhea
Water Movements
Pancreatic Polypeptide
Jejunum
Intravenous Infusions
Intravenous Administration
Reference Values
Perfusion
Sodium
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pancreatic cholera syndrome : Effect of a synthetic somatostatin analog on intestinal water and ion transport. / Santangelo, W. C.; O'Dorisio, T. M.; Kim, J. G.; Severino, G.; Krejs, G. J.

In: Annals of Internal Medicine, Vol. 103, No. 3, 04.12.1985, p. 363-367.

Research output: Contribution to journalArticle

Santangelo, W. C. ; O'Dorisio, T. M. ; Kim, J. G. ; Severino, G. ; Krejs, G. J. / Pancreatic cholera syndrome : Effect of a synthetic somatostatin analog on intestinal water and ion transport. In: Annals of Internal Medicine. 1985 ; Vol. 103, No. 3. pp. 363-367.
@article{a563194e02d24474a42a9949f0fa087a,
title = "Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport",
abstract = "The effect of a synthetic somatostatin analog was studied in a patient with severe secretory diarrhea due to pancreatic cholera syndrome. Basal intestinal perfusion studies indicated an absence of water and sodium absorption, and active chloride secretion in the small bowel. Intravenous administration of the somatostatin analog (1 μg/kg.hr) changed zero net water movement to absorption (122 mL/30 cm of the jejunum per hour). Chloride secretion changed to absorption (5.0 to 7.9 meq/30 cm.h), and plasma vasoactive intestinal polypeptide concentration was reduced from 330 to 45 pmol/L (normal, less than 51). When the analog was given subcutaneously, 100 μg twice daily, stool weight decreased, and plasma vasoactive intestinal polypeptide concentration fell toward the normal range (67 pmol/L). Plasma concentration of pancreatic polypeptide was initially elevated and dropped during intravenous infusion of somatostatin analog but returned to baseline on maintenance therapy with the analog delivered subcutaneously. The patient has not had further diarrhea during 9 months of therapy.",
author = "Santangelo, {W. C.} and O'Dorisio, {T. M.} and Kim, {J. G.} and G. Severino and Krejs, {G. J.}",
year = "1985",
month = "12",
day = "4",
language = "English (US)",
volume = "103",
pages = "363--367",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Pancreatic cholera syndrome

T2 - Effect of a synthetic somatostatin analog on intestinal water and ion transport

AU - Santangelo, W. C.

AU - O'Dorisio, T. M.

AU - Kim, J. G.

AU - Severino, G.

AU - Krejs, G. J.

PY - 1985/12/4

Y1 - 1985/12/4

N2 - The effect of a synthetic somatostatin analog was studied in a patient with severe secretory diarrhea due to pancreatic cholera syndrome. Basal intestinal perfusion studies indicated an absence of water and sodium absorption, and active chloride secretion in the small bowel. Intravenous administration of the somatostatin analog (1 μg/kg.hr) changed zero net water movement to absorption (122 mL/30 cm of the jejunum per hour). Chloride secretion changed to absorption (5.0 to 7.9 meq/30 cm.h), and plasma vasoactive intestinal polypeptide concentration was reduced from 330 to 45 pmol/L (normal, less than 51). When the analog was given subcutaneously, 100 μg twice daily, stool weight decreased, and plasma vasoactive intestinal polypeptide concentration fell toward the normal range (67 pmol/L). Plasma concentration of pancreatic polypeptide was initially elevated and dropped during intravenous infusion of somatostatin analog but returned to baseline on maintenance therapy with the analog delivered subcutaneously. The patient has not had further diarrhea during 9 months of therapy.

AB - The effect of a synthetic somatostatin analog was studied in a patient with severe secretory diarrhea due to pancreatic cholera syndrome. Basal intestinal perfusion studies indicated an absence of water and sodium absorption, and active chloride secretion in the small bowel. Intravenous administration of the somatostatin analog (1 μg/kg.hr) changed zero net water movement to absorption (122 mL/30 cm of the jejunum per hour). Chloride secretion changed to absorption (5.0 to 7.9 meq/30 cm.h), and plasma vasoactive intestinal polypeptide concentration was reduced from 330 to 45 pmol/L (normal, less than 51). When the analog was given subcutaneously, 100 μg twice daily, stool weight decreased, and plasma vasoactive intestinal polypeptide concentration fell toward the normal range (67 pmol/L). Plasma concentration of pancreatic polypeptide was initially elevated and dropped during intravenous infusion of somatostatin analog but returned to baseline on maintenance therapy with the analog delivered subcutaneously. The patient has not had further diarrhea during 9 months of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022007264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022007264&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - 363

EP - 367

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -